Oncolytics Biotech Stock Current Ratio
| ONC Stock | CAD 0.87 0.02 2.25% |
Oncolytics Biotech fundamentals help investors to digest information that contributes to Oncolytics Biotech's financial success or failures. It also enables traders to predict the movement of Oncolytics Stock. The fundamental analysis module provides a way to measure Oncolytics Biotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Oncolytics Biotech stock.
| Last Reported | Projected for Next Year | ||
| Current Ratio | 2.82 | 2.68 |
Oncolytics | Current Ratio |
Oncolytics Biotech Company Current Ratio Analysis
Oncolytics Biotech's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Oncolytics Biotech Current Ratio | 8.81 X |
Most of Oncolytics Biotech's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Oncolytics Biotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Oncolytics Current Ratio Driver Correlations
Understanding the fundamental principles of building solid financial models for Oncolytics Biotech is extremely important. It helps to project a fair market value of Oncolytics Stock properly, considering its historical fundamentals such as Current Ratio. Since Oncolytics Biotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Oncolytics Biotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Oncolytics Biotech's interrelated accounts and indicators.
Click cells to compare fundamentals
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
| Competition |
Oncolytics Price To Sales Ratio
Price To Sales Ratio |
|
In accordance with the recently published financial statements, Oncolytics Biotech has a Current Ratio of 8.81 times. This is 202.75% higher than that of the Biotechnology sector and 25.86% higher than that of the Health Care industry. The current ratio for all Canada stocks is notably lower than that of the firm.
Oncolytics Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Oncolytics Biotech's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Oncolytics Biotech could also be used in its relative valuation, which is a method of valuing Oncolytics Biotech by comparing valuation metrics of similar companies.Oncolytics Biotech is currently under evaluation in current ratio category among its peers.
Oncolytics Biotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of Oncolytics Biotech from analyzing Oncolytics Biotech's financial statements. These drivers represent accounts that assess Oncolytics Biotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Oncolytics Biotech's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 122.5M | 94.0M | 128.1M | 118.2M | 135.9M | 137.3M | |
| Enterprise Value | 91.6M | 53.4M | 116.8M | 83.7M | 96.2M | 118.0M |
Oncolytics Fundamentals
| Return On Equity | -1.89 | ||||
| Return On Asset | -0.74 | ||||
| Current Valuation | 63.77 M | ||||
| Shares Outstanding | 86.42 M | ||||
| Shares Owned By Insiders | 4.35 % | ||||
| Shares Owned By Institutions | 1.62 % | ||||
| Number Of Shares Shorted | 422.48 K | ||||
| Price To Earning | (4.18) X | ||||
| Price To Book | 13.14 X | ||||
| EBITDA | (34.88 M) | ||||
| Net Income | (31.71 M) | ||||
| Cash And Equivalents | 11.67 M | ||||
| Cash Per Share | 0.72 X | ||||
| Total Debt | 14.2 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 8.81 X | ||||
| Book Value Per Share | 0.07 X | ||||
| Cash Flow From Operations | (26.97 M) | ||||
| Short Ratio | 3.79 X | ||||
| Earnings Per Share | (0.41) X | ||||
| Target Price | 4.69 | ||||
| Number Of Employees | 28 | ||||
| Beta | 1.49 | ||||
| Market Capitalization | 76.92 M | ||||
| Total Asset | 20.19 M | ||||
| Retained Earnings | (477.71 M) | ||||
| Working Capital | 12.19 M | ||||
| Current Asset | 26.92 M | ||||
| Current Liabilities | 2.71 M | ||||
| Net Asset | 20.19 M |
About Oncolytics Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Oncolytics Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Oncolytics Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Oncolytics Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Oncolytics Biotech
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Oncolytics Biotech position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Oncolytics Biotech will appreciate offsetting losses from the drop in the long position's value.Moving together with Oncolytics Stock
Moving against Oncolytics Stock
| 0.82 | WCN | Waste Connections | PairCorr |
| 0.72 | TDG | TDG Gold Corp | PairCorr |
| 0.7 | PCAA-P | PC 1 Corp | PairCorr |
| 0.56 | VGZ | Vista Gold | PairCorr |
| 0.56 | SBI | Serabi Gold PLC | PairCorr |
The ability to find closely correlated positions to Oncolytics Biotech could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Oncolytics Biotech when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Oncolytics Biotech - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Oncolytics Biotech to buy it.
The correlation of Oncolytics Biotech is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Oncolytics Biotech moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Oncolytics Biotech moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Oncolytics Biotech can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. To learn how to invest in Oncolytics Stock, please use our How to Invest in Oncolytics Biotech guide.You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.